Biofil Chemicals & Pharmaceuticals Ltd Stock Price Today (NSE: BIOFILCHEM)
Fundamental Score
Biofil Chemicals & Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Biofil Chemicals & Pharmaceuticals Ltd share price today is ₹25.79, down 4.48% on NSE/BSE as of 30 March 2026. Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹60.21 (Cr). The 52-week high for BIOFILCHEM share price is ₹57.19 and the 52-week low is ₹27.51. At a P/E ratio of 21.13x, BIOFILCHEM is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 3.03% and a debt-to-equity ratio of 0.00.
Biofil Chemicals & Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Biofil Chemicals & Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Biofil Chemicals & Pharmaceuticals Share Price: A Financial Stability Analysis
The pharmaceutical industry, often considered defensive due to inelastic demand for essential medicines, faces increasing challenges related to pricing pressures and stringent regulatory compliance. This analysis examines the financial stability of Biofil Chemicals & Pharmaceuticals Ltd, focusing on its current market position as reflected in its Biofil Chemicals & Pharmaceuticals share price of ₹35.889999. This assessment utilizes key financial ratios and a comparison with sector peers to provide insights into the company's overall health.
Currently, Biofil Chemicals & Pharmaceuticals boasts a Price-to-Earnings (PE) ratio of 21.13. This suggests that investors are paying ₹21.13 for every rupee of earnings the company generates. While this figure can be interpreted in various ways, it is crucial to compare it with industry peers. For instance, examining
Mankind Pharma Ltd and its management quality, as perceived by the market reflected in its valuation, offers a comparative perspective. Market perception of management's ability to execute growth strategies significantly influences investor confidence and, consequently, stock valuation.A critical aspect of this analysis is the Return on Capital Employed (ROCE) of 4.12%. This indicates the efficiency with which Biofil Chemicals & Pharmaceuticals is utilizing its capital to generate profits. In the context of building a sustainable economic moat, a low ROCE suggests limitations in competitive advantage. A higher ROCE generally implies a stronger ability to reinvest profits at attractive rates and ward off competition. The 4.12% ROCE raises concerns about the company's long-term ability to sustain its market position against competitors like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, who potentially have higher reinvestment rates. The impact of lower ROCE can be less opportunity to grow at scale. This is especially important in pharmaceuticals as expansion is often capital intensive.
This financial analysis is a segment of a comprehensive 80-parameter fundamental audit, meticulously verified by Sweta Mishra, to ensure a robust and unbiased evaluation. This analysis uses only observational language and should not be interpreted as a recommendation to buy, sell, or hold Biofil Chemicals & Pharmaceuticals shares.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Biofil Chemicals & Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BIOFILCHEM across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 21.13 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (300.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (461.83%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (112.67x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (3.03%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.12%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (3.56%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Limited Growth History (2.38% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-14.28% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-14.28% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 0.08%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Biofil Chemicals & Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Biofil Chemicals & Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About BIOFILCHEM (Biofil Chemicals & Pharmaceuticals Ltd)
Biofil Chemicals & Pharmaceuticals Ltd is a dynamic and innovative pharmaceutical company dedicated to advancing healthcare solutions. The company operates with a commitment to qua...lity, safety, and efficacy in the development, manufacturing, and distribution of a diverse range of pharmaceutical products. Biofilchem's core focus lies in addressing unmet medical needs and improving patient outcomes through cutting-edge research and development. Their state-of-the-art manufacturing facilities adhere to stringent international quality standards, ensuring that every product meets the highest level of excellence. They are driven by a team of experienced professionals and scientists, dedicated to discovering, developing, and delivering innovative therapies that make a meaningful difference in people's lives. Biofilchem is committed to ethical business practices and environmental sustainability, reflecting their responsibility towards society. Biofilchem stands as a multifaceted pharmaceutical entity, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. Their expertise extends to the intricate synthesis of essential drug components and the formulation of safe and effective medications. They have built a reputation for providing high-quality, affordable medicines across various therapeutic areas, including but not limited to anti-infectives, cardiovascular, and central nervous system treatments. Beyond in-house production, Biofilchem actively collaborates with other pharmaceutical companies, offering contract manufacturing services that leverage their advanced facilities and regulatory expertise. This collaborative approach allows them to contribute to the broader healthcare ecosystem, ensuring a reliable supply of quality medications to meet growing demands. At the heart of Biofilchem's philosophy is a patient-centric approach, driving them to constantly innovate and improve their product offerings. They strive to understand the evolving needs of healthcare providers and patients, focusing on developing user-friendly formulations and convenient dosage forms. The company invests significantly in research and development, exploring novel drug delivery systems and developing generic versions of essential medicines. This commitment to innovation ensures access to affordable healthcare for a wider population. Biofilchem's dedication to quality, innovation, and ethical practices positions them as a trusted partner in the pharmaceutical industry, contributing to a healthier future for all.
Company Details
Key Leadership
BIOFILCHEM Share Price: Frequently Asked Questions
What is the current share price of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)?
As of 30 Mar 2026, 12:02 pm IST, Biofil Chemicals & Pharmaceuticals Ltd share price is ₹25.79. The BIOFILCHEM stock has a market capitalisation of ₹60.21 (Cr) on NSE/BSE.
Is BIOFILCHEM share price Overvalued or Undervalued?
BIOFILCHEM share price is currently trading at a P/E ratio of 21.13x, compared to the industry average of 31.77x. Based on this relative valuation, the Biofil Chemicals & Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of BIOFILCHEM share price?
The 52-week high of BIOFILCHEM share price is ₹57.19 and the 52-week low is ₹27.51. These values are updated daily from NSE/BSE price data.
What factors affect the Biofil Chemicals & Pharmaceuticals Ltd share price?
Key factors influencing BIOFILCHEM share price include quarterly earnings growth (Sales Growth: 461.83%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Biofil Chemicals & Pharmaceuticals Ltd a good stock for long-term investment?
Biofil Chemicals & Pharmaceuticals Ltd shows a 5-year Profit Growth of -14.28% and an ROE of 3.03%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in BIOFILCHEM shares.
How does Biofil Chemicals & Pharmaceuticals Ltd compare with its industry peers?
Biofil Chemicals & Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare BIOFILCHEM share price P/E of 21.13x and ROE of 3.03% against the industry averages to determine competitive standing.
What is the P/E ratio of BIOFILCHEM and what does it mean?
BIOFILCHEM share price has a P/E ratio of 21.13x compared to the industry average of 31.77x. Investors pay ₹21 for every ₹1 of annual earnings.
How is BIOFILCHEM performing according to Bull Run's analysis?
BIOFILCHEM has a Bull Run fundamental score of 45.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BIOFILCHEM belong to?
BIOFILCHEM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Biofil Chemicals & Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for BIOFILCHEM?
BIOFILCHEM has an ROE of 3.03%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Biofil Chemicals & Pharmaceuticals Ltd generates profits from shareholders capital.
How is BIOFILCHEM debt-to-equity ratio and what does it indicate?
BIOFILCHEM has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is BIOFILCHEM dividend yield and is it a good dividend stock?
BIOFILCHEM offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Biofil Chemicals & Pharmaceuticals Ltd shares.
How has BIOFILCHEM share price grown over the past 5 years?
BIOFILCHEM has achieved 5-year growth rates of: Sales Growth 2.38%, Profit Growth -14.28%, and EPS Growth -14.28%.
What is the promoter holding in BIOFILCHEM and why does it matter?
Promoters hold 46.79% of BIOFILCHEM shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Biofil Chemicals & Pharmaceuticals Ltd.
What is BIOFILCHEM market capitalisation category?
BIOFILCHEM has a market capitalisation of ₹60 crores, placing it in the Small-cap category.
How volatile is BIOFILCHEM stock?
BIOFILCHEM has a beta of N/A. A beta > 1 suggests the Biofil Chemicals & Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BIOFILCHEM operating profit margin trend?
BIOFILCHEM has a 5-year average Operating Profit Margin (OPM) of 3.56%, indicating the company's operational efficiency.
How is BIOFILCHEM quarterly performance?
Recent quarterly performance shows Biofil Chemicals & Pharmaceuticals Ltd YoY Sales Growth of 461.83% and YoY Profit Growth of 300.00%.
What is the institutional holding pattern in BIOFILCHEM?
BIOFILCHEM has FII holding of 0.00% and DII holding of 0.08%. Significant institutional holding often suggests professional confidence in the Biofil Chemicals & Pharmaceuticals Ltd stock.